Rhythm Pharmaceuticals, Inc.
RYTM
Clasificación en acciones
#3014
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Precio por acción
$88.37
Última sincronización: 2026-10-19
Capitalización bursátil
$6.08B
Cambio (1 día)
2.55%
Cambio (1 año)
-21.37%
País
US
Comercio Rhythm Pharmaceuticals, Inc. (RYTM)
Categoría
Healthcare
Ratio P/S de Rhythm Pharmaceuticals, Inc. (RYTM)
Ratio P/S al October 2026 TTM: 24.79
Según los informes financieros más recientes y el precio de las acciones de Rhythm Pharmaceuticals, Inc., el ratio P/S actual (TTM) es 24.79. Al final de 2023, el ratio P/S era 34.24.
Historial del ratio P/S de Rhythm Pharmaceuticals, Inc. desde 2012 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 24.79 | -5.52% |
| 2024 | 26.24 | -23.37% |
| 2023 | 34.24 | -46.67% |
| 2022 | 64.21 | -59.09% |
| 2021 | 156.95 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | -59.57% |
US
|
|
| 40.55 | 63.57% |
US
|
|
| 3.96 | -84.02% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -59.07% |
NL
|
